Ambrx is now officially part of Johnson & Johnson Innovative Medicine With our world-class team and novel ADC product candidates, we have exciting opportunities ahead to advance and deliver novel targeted therapies for patients with cancer. Read here: https://lnkd.in/exgCCsa7
Ambrx
Biotechnology Research
San Diego, CA 9,219 followers
Pioneer and Leader in Next Generation Antibody Drug Conjugates Using Engineered Precision Biologics
Über uns
Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology.
- Website
-
http://www.ambrx.com/
External link for Ambrx
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- San Diego, CA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2003
Standorte
-
Primäre
Wegbeschreibung erhalten
10975 N Torrey Pines Rd
San Diego, CA 92037, US
Employees at Ambrx
Aktualisierungen
-
Today we entered into a definitive agreement to be acquired by Johnson & Johnson. We are excited to join a global organization and accelerate our promising pipeline of next-gen ADCs for patients in need of targeted treatment options. Click here for more information and cautionary statements: https://bit.ly/3NVXqKl
Ambrx Announces Sale to Johnson & Johnson
globenewswire.com
-
Our CEO Daniel J. O'Connor comments on Ambrx's transformational year and the Company's addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). Learn more: https://bit.ly/3GEum65
-
Ambrx today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. For more information: https://bit.ly/3GEum65
-
ARX517, Ambrx's PSMA–directed antibody-drug conjugate (ADC), demonstrated promising safety and efficacy in the APEX-01 trial in patients with metastatic castration-resistant #prostatecancer (mCRPC). No serious adverse events or DLTs were observed in the Phase 1/2 clinical trial. Read more in Targeted Oncology.
ARX517 Shows Promising Safety and Efficacy in mCRPC
targetedonc.com
-
Updated results from the Phase 1/2 APEX-01 clinical trial of ARX517 demonstrate continued safety and anti-tumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC). Read more in Urology Times. https://bit.ly/484KUj0 #ProstateCancer #AntibodyDrugConjugate
ARX517 demonstrates continued safety and efficacy in mCRPC
-
Our Chief Clinical Officer, Sandra Aung, Ph.D., comments on Ambrx's ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration resistant prostate cancer (mCRPC). Read more: https://bit.ly/410TRaP
-
NOW HIRING!! Check out this great REMOTE opportunity to join our dynamic team!
Senior Clinical Data Manager - Ambrx, Inc. - Career Page
ambrxinc.applytojob.com
-
Ambrx today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1/2 dose escalation and dose expansion clinical trial in metastatic castration resistant prostate cancer (mCRPC). For details: https://bit.ly/410TRaP
-
John Shen, MD, spoke with OncLive about the unique features associated with the use of Ambrx's PSMA–directed antibody-drug conjugate (ADC) ARX517 in patients with metastatic castration-resistant prostate cancer (mCRPC) and highlighted data presented at #ESMO23 from the ongoing Phase 1/2 APEX-01 trial of ARX517. For more: https://bit.ly/473VzKK #ProstateCancer #AntibodyDrugConjugate
Dr Shen on the Tolerability and Efficacy of ARX517 in mCRPC
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Ambrx
9 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 75.0M